Orexigen Therapeutics Inc.
News and overview for Orexigen Therapeutics Inc.
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) [Press Release]
PRNewswire | 9 hours 12 minutes ago
...Rule 5635(c)(4). Orexigen Therapeutics, Inc. is a biopharmaceutical...Chief Financial Officer of Orexigen Therapeutics,Inc., +1-858-875-8600...212-301-7216, for Orexigen Therapeutics, Inc.
Four Senior Executives Join Orexigen(R) Therapeutics Management Team [Press Release]
PRNewswire | 1 day 9 hours 12 minutes ago
...Executives Join Orexigen(R) Therapeutics Management Team Seasoned...PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. today announced that four...successful approvals. Orexigen Therapeutics, Inc. is a biopharmaceutical...
Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity
News-Medical.Net | 27 days 18 hours 52 minutes ago
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity
Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave
News-Medical.Net | 29 days 21 hours 58 minutes ago
Orexigen® ( )Therapeutics, Inc (Nasdaq: OREX) today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity. These data were presented during a panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.
Orexigen 3rd-quarter loss narrows on lower costs
Forbes | 19 days 12 hours 36 minutes ago
SAN DIEGO -- Development-stage biotechnology company Orexigen Therapeutics Inc. said late Wednesday its third-quarter loss narrowed on lower costs following the end of late-stage development for the obesity drug candidate Contrave.
Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results [Press Release]
PRNewswire | 20 days 1 hour 11 minutes ago
SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society [Press Release]
PRNewswire | 28 days 7 hours 52 minutes ago
SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk [Press Release]
PRNewswire | 31 days 6 hours 12 minutes ago
SAN DIEGO, Oct. 24 /PRNewswire-FirstCall/ -- Orexigen(R) ( )Therapeutics, Inc
Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009 [Press Release]
PRNewswire | 26 days 3 hours 11 minutes ago
...days following the call. Orexigen Therapeutics, Inc. is a biopharmaceutical company...Chief Financial Officer of Orexigen Therapeutics,Inc., +1-858-875-8600...1-212-301-7173, for Orexigen Therapeutics, Inc.
Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results [Press Release]
PRNewswire | 110 days 7 hours 41 minutes ago
SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients [Press Release]
PRNewswire | 55 days 16 hours 7 minutes ago
SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM) [Press Release]
PRNewswire | 56 days 8 hours 9 minutes ago
...PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical...following the call. Orexigen Therapeutics, Inc. is a biopharmaceutical...CONTACT: Graham Cooper of Orexigen Therapeutics, Inc., +1-858-875...
Orexigen obesity drug shows added benefits: studies
Yahoo! | 31 days 4 hours 49 minutes ago
NEW YORK (Reuters) – Nearly half of patients who completed 56 weeks of treatment with Orexigen Therapeutics Inc's experimental obesity treatment, Contrave, lost at least 10 percent of their weight in a late-stage study and the drug also appeared to help cholesterol and blood sugar levels.
Sign up for FDLI SmartBrief
Company Overview
| Company: | Orexigen Therapeutics Inc. |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.orexigen.com |
Orexigen Therapeutics thinks it has the skinny on how to stay trim. The company is developing drugs, under the names Contrave and Empatic (formerly Excalia), intended for use by obese people who are trying to get a grip on the urge to over-eat. The products are designed to control appetite from the central nervous system and contain some of the same chemicals used in drugs approved for the treatment of smoking, alcoholism, and opiate addiction. The development-stage company is conducting late-stage clinical trials on its top two drug candidates.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0.1 (2008) |
|---|---|
| One-year % Growth in Sales | 0.0 (2008) |
| Net Income in U.S. Dollars (mil.) | -93.2 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 43 (2008) |
| One-year % Growth in Number of Employees | 59.3 (2008) |
| Fiscal Year-End | December |